INTRODUCING THE WORLD'S FIRST AND ONLY FMD WITH TRUSENSE THREAT QUALIFICATION Recent IRadimed News Subscribe to Email Alerts Sign up with your email address to receive the latest news and updates regarding IRadimed. SIGN UP We respect your privacy. IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Increases full-year 2021 financial guidance Oct 29, 2021 2021 3rd Quarter Earnings Conference Call IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens on Friday, October 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Oct 8, 2021 IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and nonGAAP diluted EPS of $0.14 Issues Q3 and full year 2021 financial guidance Jul 30, 2021 IRADIMED CORPORATION to Hold 2021 Second Quarter Financial Results Conference Call on July 30th Winter Springs, Florida, July 7, 2021 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 second quarter financial results before the market opens on Friday, July 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Jul 7, 2021 IRADIMED CORPORATION Announces First Quarter 2021 Financial Results Reports first quarter 2021 revenue of $9.2 million, GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.13 Reports combined cash and investments of $52.7 million as of March 31, 2021 Apr 30, 2021 IRADIMED CORPORATION to Hold 2021 First Quarter Financial Results Conference Call on April 30th IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 first quarter financial results before the market opens on Friday, April 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Apr 9, 2021 IRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results Reports fourth quarter 2020 revenue of $8.5 million, GAAP diluted EPS of $0.05 and non-GAAP diluted EPS of $0.07 Reports combined cash and investments of $52.0 million as of December 31, 2020 Winter Springs, Florida, February 4, 2021 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and nonmagnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months and year ended December 31, 2020. Feb 4, 2021 IRADIMED CORPORATION to Hold 2020 Fourth Quarter Financial Results Conference Call on February 4th IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4th. Jan 27, 2021 IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results Reports third quarter 2020 revenue of $7.7 million, GAAP diluted EPS of $0.09 and non-GAAP diluted EPS of $0.11 Reports combined cash and investments of $49.9 million as of September 30, 2020 Oct 30, 2020 IRadimed to Hold Third Quarter Financial Results Conference Call on October 30th IRadimed announced today that the Company will release its 2020 third quarter financial results before the market opens on Friday, October 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Oct 8, 2020 IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results Reports second quarter 2020 revenue of $6.8 million, GAAP diluted EPS of $(0.17) and non-GAAP diluted EPS of $0.05 Reports combined cash and investments of $47.8 million as of June 30, 2020 Jul 30, 2020 IRADIMED CORPORATION to Hold 2020 Second Quarter Financial Results Conference Call on July 30th Jul 16, 2020 IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer Winter Springs, Florida, May 29, 2020 – IRADIMED CORPORATION (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s President and Chief Executive Officer after the departure of Leslie McDonnell, who separated from the Company effective May 28, 2020. May 29, 2020 IRADIMED CORPORATION Announces Issuance of U.S. Patent Winter Springs, Florida, May 11, 2020 IRADIMED CORPORATION (NASDAQ:IRMD), today announced the issuance by the U.S. Patent and Trademark Office of a patent that expands on previous claims pertaining to the wireless remote control of IV infusion pumps. May 11, 2020 IRADIMED CORPORATION Announces First Quarter 2020 Financial Results IRADIMED CORPORATION Announces First Quarter 2020 Financial Results Reports first quarter 2020 revenue of $8.7 million, GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.18 Reports combined cash and investments of $47.4 million as of March 31, 2020 Apr 30, 2020 2020 First Quarter Financial Results Conference Call on April 30th IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 first quarter financial results before the market opens on Thursday, April 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Apr 16, 2020 IRADIMED CORPORATION Withdraws 2020 Financial Guidance IRADIMED CORPORATION (NASDAQ: IRMD) announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is withdrawing its first quarter and full year 2020 financial guidance due to the uncertainty created by COVID-19. Apr 7, 2020 IRADIMED CORPORATION Announces the Appointment of Lynn Neuhardt as Vice President of Research and Development Winter Springs, Florida, March 12, 2020 – IRADIMED CORPORATION (NASDAQ: IRMD) announced the appointment of Lynn Neuhardt as Vice President of Research and Development, effective March 26, 2020. Mr. Neuhardt will report to Leslie McDonnell, President and Chief Executive Officer. Mar 12, 2020 IRADIMED CORPORATION Announces Retirement of Francis Casey and the Appointment of Steven Kachelmeyer announced the retirement of Francis Casey, Vice President of Regulatory Affairs and Quality Assurance, effective June 30, 2020 after leading the Company’s regulatory efforts since 2004. IRADIMED appointed Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance, succeeding Mr. Casey, effective March 10, 2020. Feb 26, 2020 IRADIMED CORPORATION Announces Fourth Quarter 2019 Financial Results Reports fourth quarter 2019 revenue of $10.9 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.30 Renewed CE Mark for patient vital signs monitor and shipped associated backlog during the fourth quarter 2019 Announces 2020 full year and first quarter financial guidance Feb 6, 2020 IRADIMED CORPORATION to Hold 2019 Fourth Quarter Financial Results Conference Call on February 6th Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 7783873. Jan 22, 2020 IRADIMED CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales Jan 7, 2020 CE Mark Renewal Process MRI Compatible Patient Vital Signs Monitoring System Completed IRaadimed today announced that it resumed shipments of its MRI compatible patient vital signs monitoring systems into European Commission markets after completing the CE Mark renewal process. Dec 12, 2019 IRADIMED CORPORATION Announces Third Quarter 2019 Financial Results Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Updates full-year financial guidance Oct 30, 2019 IRADIMED CORPORATION to Hold 2019 Third Quarter Financial Results Winter Springs, Florida, October 16, 2019 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 third quarter financial results before the market opens on Wednesday, October 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Oct 16, 2019 Infusion Pump Warning Letter Resolved Winter Springs, Florida, October 8, 2019 – IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. Oct 8, 2019 IRADIMED CORPORATION to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference Winter Springs, Florida, August 27, 2019 – IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chief Technology Officer and Chris Scott, Chief Financial Officer, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference in New York from September 9, 2019 to September 11, 2019. Aug 28, 2019 IRADIMED CORPORATION Announces Second Quarter 2019 Financial Results Reports second quarter 2019 revenue of $9.2 million Reports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20 Updates full year earnings guidance Jul 30, 2019 Leslie McDonnell named as President and Chief Executive Officer Winter Springs, Florida, July 29, 2019 – iRadimed Corporation (NASDAQ: IRMD) announced today that its Board of Directors unanimously appointed Leslie McDonnell, to succeed Roger Susi as President and Chief Executive Officer. Mr. Susi will step down as President and CEO on August 19, 2019 after leading the Company since its founding 27 years ago. Jul 29, 2019 IRADIMED CORPORATION Announces First Quarter 2019 Financial Results • Reports first quarter 2019 revenue of $8.4 million • Reports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 Apr 30, 2019 To access the entire IRadimed news archive please click the following link: IRADIMED NEWS ARCHIVE TERMS AND CONDITIONSPRIVACY STATEMENTCITATION REFERENCESCONTACT US © 2021 IRadimed Corporation. All rights reserved. IRadimed, the IRadimed logo, and MRidium are registered trademarks. All other trademarks are the property of their respective owners.